Physician profile
Ravi Chander
NPI 1457355729
$7,862.30
in general payments reported to CMS, 2019-2025
29 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,784 · 2020: $448 · 2021: $954 · 2022: $1,218 · 2023: $1,023 · 2024: $1,489 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,458.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,790.36 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $1,625.82 | 2019-2024 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $696.41 | 2019-2025 | |
| Biotronik INC. | $383.06 | 2022-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Novartis Pharmaceuticals Corporation | $382.62 | 2019-2025 | |
| Medtronic, INC. | $332.40 | 2021-2025 | Micra, Reveal Linq, Cobalt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $330.80 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $279.97 | 2021-2025 | Ozempic, Wegovy |
| Abbott Laboratories | $209.83 | 2019-2024 | Jot Dx |
| Medtronic Vascular, INC. | $191.82 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.43 | 2022-2025 | Lifevest |
| Atricure, INC. | $185.41 | 2022 | |
| Alnylam Pharmaceuticals INC. | $150.59 | 2019-2025 | Onpattro, Amvuttra |
| Amgen INC. | $120.80 | 2019-2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $117.34 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.19 | 2023-2025 | Verquvo, Capvaxive |
| Angiodynamics, INC. | $95.63 | 2022-2024 | Alphavac |
| Kowa Pharmaceuticals America, INC. | $92.83 | 2020-2021 | |
| Gilead Sciences, INC. | $91.85 | 2019 | |
| Esperion Therapeutics, INC. | $76.65 | 2023-2024 | Nexletol |
| Astellas Pharma US INC | $69.78 | 2019 | |
| Edwards Lifesciences Corporation | $64.63 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.78 | 2022-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $56.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.76 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $42.57 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $41.78 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.84 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $17.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Chander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.